Sublingual tablet immunotherapy improves quality of life in adults with allergic rhinoconjunctivitis
Sublingual tablet immunotherapy improves quality of life in adults with allergic rhinoconjunctivitis
Background: Allergic rhinitis with or without conjunctivitis can negatively impact many aspects of quality of life (QoL). The efficacy and safety of standardized quality (SQ) sublingual immunotherapy (SLIT) tablets have been confirmed across large clinical trials in adults with grass, tree, ragweed, and house dust mite (HDM) allergic rhinitis with or without conjunctivitis. Objective: This pooled analysis investigates whether the reduction in symptom burden found across the clinical trials is supported by improvements in QoL. Methods: A total of 11 phase II/III randomized placebo-controlled trials across the SQ grass, tree, ragweed, and HDM SLIT tablets (grass: N = 3179; ragweed: N = 767; tree: N = 634; HDM: N = 2221) were included. QoL was assessed using the standardized Rhinitis Quality of Life Questionnaire (RQLQ), with the exception of 3 grass trials, which used the nonstandardized version. The overall RQLQ scores were expressed as a mean of 7 domains. In the pooled analysis, treatment was used as fixed effect; and the trial, and the interaction between region/country and trial as random effects. Results: The pooled analysis showed consistent and statistically significant improvements in overall RQLQ scores across all 4 SQ SLIT tablets versus placebo (pooled estimate [95% CI], P value—grass: −0.20 [−0.28 to −0.12], P < .001; tree: −0.42 [−0.58 to −0.26], P < .001; ragweed: −0.36 [−0.55 to −0.17], P < .001; HDM: −0.28 [−0.39 to −0.17], P < .001). Furthermore, significant improvements versus placebo for all 4 SQ SLIT tablets were seen across the 7 individual domains. Conclusions: The proven efficacy of SQ SLIT tablets to reduce symptoms across 4 of the most common respiratory allergens is supported by concurrent significant improvements in RQLQ scores overall and for all 7 domains.
Allergic rhinoconjunctivitis, Grass pollen allergy, HDM allergy, Pooled analysis, Quality of life, RQLQ, RQLQ domains, Ragweed allergen, Sublingual immunotherapy, Tree pollen allergy
Blaiss, Michael S
5bfffae8-a07d-4a12-bf0d-ba8553b7b837
Durham, Stephen R.
2c4a2deb-84be-4796-9566-fdcddfe29d8b
Bernstein, David
09f7ab15-a526-4e48-9d8f-2653c3baf86b
Stranzl, Thomas
f146fd5f-ab9a-43af-bbfc-ce65c1e43c58
Lindholm, Morten
c0ec96ba-52ce-4137-910a-a00302b5e94f
Nolte, Hendrik
1f5625c7-8379-4398-bf26-51eb194edc5c
Andersen, Kristian Funding
e1c18fbf-3ee6-4d4d-b9e9-2519f4e3bbcf
Roberts, Graham
ea00db4e-84e7-4b39-8273-9b71dbd7e2f3
Blaiss, Michael S
5bfffae8-a07d-4a12-bf0d-ba8553b7b837
Durham, Stephen R.
2c4a2deb-84be-4796-9566-fdcddfe29d8b
Bernstein, David
09f7ab15-a526-4e48-9d8f-2653c3baf86b
Stranzl, Thomas
f146fd5f-ab9a-43af-bbfc-ce65c1e43c58
Lindholm, Morten
c0ec96ba-52ce-4137-910a-a00302b5e94f
Nolte, Hendrik
1f5625c7-8379-4398-bf26-51eb194edc5c
Andersen, Kristian Funding
e1c18fbf-3ee6-4d4d-b9e9-2519f4e3bbcf
Roberts, Graham
ea00db4e-84e7-4b39-8273-9b71dbd7e2f3
Blaiss, Michael S, Durham, Stephen R., Bernstein, David, Stranzl, Thomas, Lindholm, Morten, Nolte, Hendrik, Andersen, Kristian Funding and Roberts, Graham
(2024)
Sublingual tablet immunotherapy improves quality of life in adults with allergic rhinoconjunctivitis.
Journal of Allergy and Clinical Immunology: In Practice.
(doi:10.1016/j.jaip.2024.01.038).
Abstract
Background: Allergic rhinitis with or without conjunctivitis can negatively impact many aspects of quality of life (QoL). The efficacy and safety of standardized quality (SQ) sublingual immunotherapy (SLIT) tablets have been confirmed across large clinical trials in adults with grass, tree, ragweed, and house dust mite (HDM) allergic rhinitis with or without conjunctivitis. Objective: This pooled analysis investigates whether the reduction in symptom burden found across the clinical trials is supported by improvements in QoL. Methods: A total of 11 phase II/III randomized placebo-controlled trials across the SQ grass, tree, ragweed, and HDM SLIT tablets (grass: N = 3179; ragweed: N = 767; tree: N = 634; HDM: N = 2221) were included. QoL was assessed using the standardized Rhinitis Quality of Life Questionnaire (RQLQ), with the exception of 3 grass trials, which used the nonstandardized version. The overall RQLQ scores were expressed as a mean of 7 domains. In the pooled analysis, treatment was used as fixed effect; and the trial, and the interaction between region/country and trial as random effects. Results: The pooled analysis showed consistent and statistically significant improvements in overall RQLQ scores across all 4 SQ SLIT tablets versus placebo (pooled estimate [95% CI], P value—grass: −0.20 [−0.28 to −0.12], P < .001; tree: −0.42 [−0.58 to −0.26], P < .001; ragweed: −0.36 [−0.55 to −0.17], P < .001; HDM: −0.28 [−0.39 to −0.17], P < .001). Furthermore, significant improvements versus placebo for all 4 SQ SLIT tablets were seen across the 7 individual domains. Conclusions: The proven efficacy of SQ SLIT tablets to reduce symptoms across 4 of the most common respiratory allergens is supported by concurrent significant improvements in RQLQ scores overall and for all 7 domains.
Text
1-s2.0-S2213219824001405-main
- Proof
More information
Accepted/In Press date: 25 January 2024
e-pub ahead of print date: 1 February 2024
Additional Information:
Publisher Copyright:
© 2024 The Authors
Keywords:
Allergic rhinoconjunctivitis, Grass pollen allergy, HDM allergy, Pooled analysis, Quality of life, RQLQ, RQLQ domains, Ragweed allergen, Sublingual immunotherapy, Tree pollen allergy
Identifiers
Local EPrints ID: 487221
URI: http://eprints.soton.ac.uk/id/eprint/487221
ISSN: 2213-2198
PURE UUID: 73ea6f8f-3057-40de-bd0f-335bfb1ed882
Catalogue record
Date deposited: 16 Feb 2024 11:24
Last modified: 23 Apr 2024 01:39
Export record
Altmetrics
Contributors
Author:
Michael S Blaiss
Author:
Stephen R. Durham
Author:
David Bernstein
Author:
Thomas Stranzl
Author:
Morten Lindholm
Author:
Hendrik Nolte
Author:
Kristian Funding Andersen
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
